Name: Receivables Turnover

Definition: Receivables turnover tells you how quickly the company collects payments from customers after making sales on credit. A high turnover means customers pay on time and cash flows smoothly. Slow turnover suggests delayed collections, which can create cash shortages and financing stress.

Interpretation:
• In '2021', ACHV's receivables turnover was 0.00, showing efficiency in collecting outstanding receivables. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2021' stood at 4.65.
• In '2022', ACHV's receivables turnover was 0.00, showing efficiency in collecting outstanding receivables. The figure remained stable compared to '2021'. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2022' stood at 4.94. Industry average increased by 0.30 compared to previous year.
• In '2023', ACHV's receivables turnover was 0.00, showing efficiency in collecting outstanding receivables. The figure remained stable compared to '2022'. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2023' stood at 5.50. Industry average increased by 0.56 compared to previous year.
• In '2024', ACHV's receivables turnover was 0.00, showing efficiency in collecting outstanding receivables. The figure remained stable compared to '2023'. Industry average for Biotechnology: In Vitro & In Vivo Diagnostic Substances in '2024' stood at 4.90. Industry average declined by 0.60 from previous year.
Overall, ACHV's receivables turnover has remained generally stable over the past 4 years.

Formula: Receivables Turnover = Net Credit Sales / Average Accounts Receivable

Good Range: Ranges 5 to 15 depending on credit terms.